ArticlePloS one2013

Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.

Emanuela Foglia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.